p27 (also known as KIP1, and encoded by CDKN1B) is regulated by multiple signal transduction pathways in normal and malignant cells. CDKN1B transcription can be regulated by the FoxO family and ...

A multicenter collaboration has identified a potential new treatment for an aggressive sarcoma arising in the nerves. The ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash ...

Insilico Medicine Inc. has disclosed substituted thiazole compounds acting as cyclin-dependent kinase (CDK) inhibitors potentially useful for the treatment of cancer. Insilico Medicine identifies CDK2 ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

My laboratory has combined biochemical, molecular, cellular, and genetic approaches to investigate the roles of CDK inhibitors in differentiation, development, and cancer biology. An additional major ...

The biopharma has three CDK2 inhibitors in development for breast ... potential opportunities to broadly advance its franchise of CDK programs,” Blueprint said in the release.

“We're very impressed with the results,” said Metzger. On the basis of previous studies, it’s believed that CDK 4/6 inhibition counteracts the development of resistance to anti-HER2 and ...

He provided a direct explanation for how external signals block cell division through CDK inhibitors and cell fate through chromatin regulators. These mechanisms are crucial in embryonic development, ...

Targeted molecular therapies — including CDK 4/6, PI3 kinase, poly(ADP)-ribose polymerase (PARP) and mammalian target of rapamycin (mTOR) inhibitors — have transformed the breast cancer ...